Johnson & Johnson’s Estimates Cut at UBS on OTC Closure (JNJ)

By
A A A
Share |

Health care giant Johnson & Johnson ( JNJ ) saw its earnings estimates lowered on Friday by analysts at UBS.

The firm said it lowered its estimates for JNJ through 2011, citing a longer-than-expected closure of the company's Washington-based over-the-counter drug facility. The company has issued a recall on some of its Benedryl and Tylenol products, after customer complaints about a moldy smell that can cause nausea and sickness.

Still, UBS maintained its "Buy" rating and $75 price target for the stock. That target represents a nearly 26% upside to the stock's Thursday closing price of $59.60.


Johnson & Johnson shares rose 37 cents, or +0.6%, in premarket trading Friday.

The Bottom Line
We have been recommending shares of JNJ since Oct.8, when the stock was trading at $60.71. The company has a 3.62% dividend yield, based on last night's closing stock price of $59.60.

Johnson & Johnson ( JNJ ) is a "recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com



This article appears in: Investing , Stocks

Referenced Stocks: JNJ

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Stocks

Referenced

80%

Most Active by Volume

34,808,125
  • $16.485 ▼ 1.58%
27,665,867
  • $130.58 ▼ 1.48%
24,432,983
  • $6.61 ▲ 0.61%
21,977,094
  • $8.60 ▼ 6.01%
18,646,682
  • $27.51 ▼ 0.61%
17,564,590
  • $3.493 ▲ 10.89%
14,208,091
  • $178.49 ▲ 4.27%
14,048,686
  • $34.45 ▼ 0.75%
As of 5/26/2015, 11:52 AM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com